McKesson MCK Business Segments
| Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Business | ||||||
| Medical-Surgical Solutions | $2.87B+0.5% | $2.99B+1.4% | $2.95B0.0% | $2.7B+2.5% | $2.85B+0.7% | |
| North American Pharmaceutical | $79.12B+2.8% | $88.32B+8.8% | $86.48B+8.1% | $82.73B+24.7% | $76.94B+17.8% | |
| Oncology & Multispecialty | $12.71B+34.8% | $13.01B+37.0% | $12.04B+31.5% | $10.66B+21.4% | $9.43B+23.7% | |
| Prescription Technology Solutions | $1.5B+11.7% | $1.5B+9.4% | $1.38B+8.8% | $1.43B+15.6% | $1.34B+13.5% | |
| Subtotal by Business | ||||||
| Medical-Surgical Solutions | $232M+2.2% | $265M-1.5% | $220M+142% | $221M+17.6% | $227M-4.9% | |
| North American Pharmaceutical | $1.16B+0.4% | $1.06B+41.8% | $852M+146% | $594M-15.4% | $1.15B+97.1% | |
| Oncology & Multispecialty | $301M+38.7% | $304M+50.5% | $332M+66.0% | $212M+43.2% | $217M+22.8% | |
| Prescription Technology Solutions | $286M+15.3% | $261M+19.2% | $244M+19.0% | $253M+24.6% | $248M+18.8% | |
| Total other segment expense, net by Business | ||||||
| Medical-Surgical Solutions | $2.64B+0.4% | $2.73B+1.7% | $2.73B-4.5% | $2.48B+1.3% | $2.63B+1.4% | |
| North American Pharmaceutical | $77.96B+2.9% | $87.27B+8.5% | $85.63B+7.5% | $82.14B+25.1% | $75.79B+17.0% | |
| Oncology & Multispecialty | $12.41B+34.7% | $12.71B+36.8% | $11.71B+30.8% | $10.45B+21.0% | $9.21B+23.7% | |
| Prescription Technology Solutions | $1.21B+10.8% | $1.24B+7.6% | $1.13B+6.8% | $1.18B+13.8% | $1.09B+10.9% | |
| Revenue derived from services (less than) (as a percent) by Business | ||||||
| Prescription Technology Solutions | 7%0.0pp | 36%0.0pp | 37%0.0pp | 38%0.0pp | 7%— | |
| Total segment expenditures for long-lived assets by Business | ||||||
| Medical-Surgical Solutions | $13M-61.8% | $24M-33.3% | $32M-23.8% | $25M-51.0% | $34M-14.5% | |
| North American Pharmaceutical | $115M+35.3% | $84M+35.5% | $74M+12.1% | $61M+103% | $85M+114% | |
| Oncology & Multispecialty | $14M-41.7% | $17M-37.0% | $23M+21.1% | $24M+33.3% | $24M0.0% | |
| Prescription Technology Solutions | $2M+100% | $1M-66.7% | $0-100% | $1M-75.0% | $1M-87.1% | |
| Other by Business | ||||||
| Medical-Surgical Solutions | $500K— | $500K+125% | $500K— | $500K— | $0— | |
| North American Pharmaceutical | -$1M+20.0% | —— | —— | —— | -$1.25M— | |
| Oncology & Multispecialty | $0+100% | $0+100% | $0+100% | $0+100% | -$250K— | |
| Prescription Technology Solutions | $0+100% | —— | —— | —— | -$1M— | |
| Total segment depreciation and amortization by Business | ||||||
| Medical-Surgical Solutions | $25M+4.2% | $26M+13.0% | $23M+4.5% | $22M-4.3% | $24M+17.1% | |
| North American Pharmaceutical | $36M+16.1% | $34M+3.0% | $32M-25.6% | $32M-33.3% | $31M-37.1% | |
| Oncology & Multispecialty | $64M+77.8% | $63M+70.3% | $71M+91.9% | $42M+10.5% | $36M+5.1% | |
| Prescription Technology Solutions | $20M-4.8% | $21M-4.5% | $20M-9.1% | $21M0.0% | $21M0.0% | |
| Foreign currency translation adjustments, net by Business | ||||||
| Medical-Surgical Solutions | $0— | $0— | $0— | $0— | $0— | |
| Oncology & Multispecialty | $0— | $0— | —— | —— | $0— | |
| Prescription Technology Solutions | $0— | $0— | $0— | $0— | $0— | |
| Total reserve balance by Business | ||||||
| Medical-Surgical Solutions | $10M-88.9% | $6M-94.6% | $39M-72.9% | $57M— | $90M+8,900% | |
| North American Pharmaceutical | $18M+63.6% | $14M— | $14M— | —— | $11M-52.2% | |
| Prescription Technology Solutions | $3M+200% | $0-100% | $0-100% | $1M-80.0% | $1M-80.0% | |
| Other adjustments by Business | ||||||
| Medical-Surgical Solutions | $0-100% | $0— | $0— | $0— | $83M— | |
| North American Pharmaceutical | $0-100% | $0-100% | —— | —— | $1.25M— | |
| Prescription Technology Solutions | -$1M+87.5% | $0— | $0— | $0— | -$8M— | |
| Non-cash charges by Business | ||||||
| Medical-Surgical Solutions | -$19M-338% | $11M+83.3% | $0— | $0— | $8M— | |
| North American Pharmaceutical | $14M-3.4% | -$3M-121% | —— | —— | $14.5M— | |
| Prescription Technology Solutions | $17M+143% | $0— | $0-100% | $0-100% | $7M— | |
| Severance and employee-related costs, net by Business | ||||||
| North American Pharmaceutical | $5M+225% | $0— | $4M+300% | $0— | -$4M-329% | |
| Restructuring Charges by Business | ||||||
| Medical-Surgical Solutions | $10M-71.4% | -$3M-116% | $19M-87.1% | $17M+467% | $35M+1,650% | |
| North American Pharmaceutical | $16M— | $1M-50.0% | $6M-90.5% | $1M— | —— | |
| Prescription Technology Solutions | $20M+186% | $0— | $0-100% | $0-100% | $7M+75.0% | |
| Payments for Restructuring by Business | ||||||
| Medical-Surgical Solutions | $3M-93.8% | $43M-2.3% | $37M+1,133% | $50M+1,150% | $48M+1,500% | |
| North American Pharmaceutical | $1M-50.0% | —— | —— | —— | $2M— | |
| Oncology & Multispecialty | $0-100% | $0-100% | $0-100% | $0-100% | $500K— | |
| Exit and other-related costs by Business | ||||||
| Medical-Surgical Solutions | $9M-67.9% | $2M-89.5% | $14M+367% | $12M+300% | $28M+833% | |
| North American Pharmaceutical | $1M-66.7% | $0-100% | $1M+200% | $1M— | $3M+300% | |
| Goodwill, transfer to held-for-sale by Business | ||||||
| Medical-Surgical Solutions | $0— | $0— | $0— | $0— | $0— | |
| North American Pharmaceutical | $0-100% | $0-100% | —— | —— | $11.5M— | |
| Oncology & Multispecialty | $2.25M— | $2.25M— | $2.25M— | $2.25M— | $0— | |
| Prescription Technology Solutions | $0— | $0— | $0— | $0— | $0— | |
| Asset impairments and accelerated depreciation by Business | ||||||
| North American Pharmaceutical | $10M— | $1M0.0% | $1M-98.4% | $0— | —— | |
| Goodwill by Business | ||||||
| Medical-Surgical Solutions | $2.51B0.0% | $2.51B0.0% | $2.51B0.0% | $2.51B-1.1% | $2.51B+2.2% | |
| North American Pharmaceutical | $2.78B+1.6% | $2.8B— | $2.78B— | —— | $2.74B-4.2% | |
| Oncology & Multispecialty | $3.96B+45.5% | $3.95B— | $3.93B— | —— | $2.72B-1.8% | |
| Prescription Technology Solutions | $2.07B+1.9% | $2.07B+2.1% | $2.07B+2.1% | $2.07B+2.1% | $2.03B+0.1% | |
| Goodwill acquired by Business | ||||||
| Medical-Surgical Solutions | $0— | $0— | $0— | $0— | $0— | |
| North American Pharmaceutical | $0-100% | $0-100% | —— | —— | $250K— | |
| Total long-lived assets by Geography | ||||||
| Foreign | $255M-16.7% | $254M— | $261M— | $330M— | $306M-8.4% | |
| United States | $3.18B+10.4% | $3.13B— | $3.1B— | $2.95B— | $2.88B+16.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does McKesson break its business down?
- McKesson (MCK) reports total revenues by business across 4 parts — Medical-Surgical Solutions, North American Pharmaceutical, Oncology & Multispecialty and Prescription Technology Solutions. Each is extracted from the segment footnotes and tracked over time.
- Where does McKesson's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in McKesson's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
